A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Abroad (travel likely)RecruitingPHASE2

Conditions

Metabolic Dysfunction-Associated Steatohepatitis · Non-alcoholic Fatty Liver Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations